Efficacy of sacituzumab govitecan versus treatment of physician’s choice in previously treated HR+ and HER2− mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trials
Background and objective: TROPiCS-02 and EVER-132-002 are phase III randomized controlled trials (RCTs) comparing sacituzumab govitecan (SG) to treatment of physician’s choice (TPC) in patients with hormone receptor-positive and human epidermal growth factor receptor 2 negative (HR+/HER2−) locally r...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-03-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359251320285 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!